Loading clinical trials...
Loading clinical trials...
A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
Conditions
Interventions
BCD-263
Opdivo
Locations
44
Belarus
Healthcare Institution "Brest Regional Oncological Dispensary"
Brest, Belarus
Health Institution "Gomel Regional Clinical Oncology Center"
Homyel, Belarus
Healthcare Institution "Minsk City Clinical Cancer Center"
Minsk, Belarus
State Institution "Republic Scientific and Practical Centre for Oncology and Medical Radiology Named after N.N.Aleksandrov"
Minsk, Belarus
Shaheed Zulfiqar Ali Bhutto Medical University
Islamabad, Pakistan
Rehman Medical Institute
Peshawar, Pakistan
Start Date
March 21, 2024
Primary Completion Date
December 1, 2025
Completion Date
March 1, 2027
Last Updated
July 8, 2025
NCT05969860
NCT06066138
NCT05039801
NCT06264180
NCT07310784
NCT06956690
Lead Sponsor
Biocad
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions